Home Featured Page 231

Featured

Latest

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Red Light Holland to Partner with Leading Fresh and Dried Mushroom...

PT249 – Hadas Alterman, Serena Wu, and Adriana Kertzer of Plant...

Filament Announces Shareholder Approval of Amalgamation and Closing of Private Placement...

Psychedelics and Perception Part 1: The First Era of Research

Red Light Holland Provides Initial FAQ in connection with Transaction with...

Psychedelic Bulletin: atai IPOs on Nasdaq; Cybin to Target Anxiety Indications;...

Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange

PTSF64 – The First Woman to Take Acid, The Drug Policy...

atai Life Sciences Announces Pricing of Upsized Initial Public Offering

Diamond Therapeutics contracts BioPharma Services for Phase 1 clinical trial

1...230231232...291 Page 231 of 291

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Red Light Holland to Partner with Leading Fresh and Dried Mushroom...

PT249 – Hadas Alterman, Serena Wu, and Adriana Kertzer of Plant...

Filament Announces Shareholder Approval of Amalgamation and Closing of Private Placement...

Psychedelics and Perception Part 1: The First Era of Research

Red Light Holland Provides Initial FAQ in connection with Transaction with...

Psychedelic Bulletin: atai IPOs on Nasdaq; Cybin to Target Anxiety Indications;...

Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange

PTSF64 – The First Woman to Take Acid, The Drug Policy...

atai Life Sciences Announces Pricing of Upsized Initial Public Offering

Diamond Therapeutics contracts BioPharma Services for Phase 1 clinical trial

EDITOR PICKS

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY